Robert Sporter, MD

The panel offers their final recommendations for physicians managing patients with asthma.

Advice for Clinicians Managing Asthma

Videos

The panel discusses the biologic drugs approved for use in children with asthma.

Biologic Options in Pediatric Asthma

The panel discusses the biologic drugs approved for use in children with asthma, including omalizumab, dupilumab, mepolizumab, and the recently approved benralizumab. They share their preferences among these options for improving lung function in pediatric patients.

Robert Sporter, MD, discusses the initial conversations he has with pediatric patients and their parents when considering biologic therapies.

Use of Biologics in Pediatric Patients and Conversations with Parents

Robert Sporter, MD, discusses the initial conversations he has with pediatric patients and their parents when considering biologic therapies, addressing the risks associated with not treating the condition, such as compromised lung function and increased steroid use. He emphasizes the importance of communicating a comprehensive treatment plan, including contingencies for cases where a particular therapy may not be effective.

 Shahzad Mustafa, MD, discusses pediatric atopic march.

Atopic March in Pediatric Patients

Shahzad Mustafa, MD, examines the pediatric atopic march, a phenomenon characterized by the sequential development of wheezing, asthma, and food allergies in children, discussing the progression and interrelationship of these conditions. He also explores the potential benefits of early intervention with medications in managing these conditions in pediatric patients.

Robert Sporter, MD

Articles